Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Sensus Healthcare, Inc. publishes a filing, an earnings call transcript or a press release.

Get SRTS alerts

About Joseph Sardano

Joseph Sardano is recorded as CEO at Sensus Healthcare, Inc. (SRTS). The newest filing on record that lists Joseph Sardano as CEO at Sensus Healthcare, Inc. (SRTS) is dated April 29, 2026. The proxy statement of Sensus Healthcare, Inc. reports total compensation of $1,417,860 for Joseph Sardano in fiscal 2025, including a base salary of $600,000. Disclosed compensation is on record for 8 fiscal years. Joseph Sardano has spoken on 9 earnings calls across 1 company, most recently for Sensus Healthcare, Inc. on February 12, 2026. Sensus Healthcare, Inc. is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Sensus Healthcare, Inc. includes Arthur Levine (CFO), Javier Rampolla (CFO), Magdalena Martinez (COO) and 5 others.

Joseph Sardano on recent calls

“Let me start by providing some context around our end-of-year activities and the wonderful news received from CMS. SRT and IGSRT are non-invasive technology that was exclusively designed, developed, and distributed by Census Healthcare.”
CEO, Sensus Healthcare, Inc. Q4 FY2025 Earnings Call ·
“Before we jump into the meat of today's call, let me address the distribution of our earnings news release earlier today. As you know, we typically issue our financial announcements after the markets close.”
CEO, Sensus Healthcare, Inc. Q3 FY2024 Earnings Call ·
“Our sales momentum continued in the second quarter of 2024 with very strong year-over-year revenue growth, along with positive net income and positive adjusted EBITDA.”
CEO, Sensus Healthcare, Inc. Q2 FY2024 Earnings Call ·
“I'm delighted to report excellent results for Q1 2024. Sensus Healthcare has seen some very positive momentum. And as the dermatology community recognizes the importance of IG-SRT to their patients and their practices as a noninvasive and highly efficacious modality to treat non-melanoma skin cancer.”
CEO, Sensus Healthcare, Inc. Q1 FY2024 Earnings Call ·
“Our second quarter financial results showed improvement over the first quarter. During Q2, we shipped 13 systems, including four SRT systems outside the US, and six SRT-100 Vision systems up from 10 systems shipped during the first quarter of 2023, but down from 33 systems shipped in the prior year quarter.”
CEO, Sensus Healthcare, Inc. Q2 FY2023 Earnings Call ·

Affiliation history

Company network

Leadership on record at Sensus Healthcare, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Sensus Healthcare, Inc. (SRTS) $600,000 $1,417,860
2024 Sensus Healthcare, Inc. (SRTS) $500,000 $1,268,030
2023 Sensus Healthcare, Inc. (SRTS) $450,000 $687,599
2022 Sensus Healthcare, Inc. (SRTS) $400,000 $754,428
2021 Sensus Healthcare, Inc. (SRTS) $375,000 $628,451
2020 Sensus Healthcare, Inc. (SRTS) $375,000 $510,006
2019 Sensus Healthcare, Inc. (SRTS) $375,000 $466,800
2018 Sensus Healthcare, Inc. (SRTS) $360,000 $538,392

Recent activity